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Summary
 
After interaction of human immunodeficiency virus type 1 (HIV-1) virions with cell surface
receptors, a series of poorly characterized events results in establishment of a viral reverse tran-
scription complex in the host cell cytoplasm. This process is coordinated in such a way that re-
verse transcription is initiated shortly after formation of the viral reverse transcription complex.
However, the mechanism through which virus entry and initiation of reverse transcription are
coordinated and how these events are compartmentalized in the infected cell are not known. In
this study, we demonstrate that viral reverse transcription complexes associate rapidly with the
host cell cytoskeleton during HIV-1 infection and that reverse transcription occurs almost en-
tirely in the cytoskeletal compartment. Interruption of actin polymerization before virus infec-
tion reduced association of viral reverse transcription complexes with the cytoskeleton. In addi-
tion, efficient reverse transcription was dependent on intact actin microfilaments. The
localization of reverse transcription to actin microfilaments was mediated by the interaction of
a reverse transcription complex component (gag MA) with actin but not vimentin (intermedi-
ate filaments) or tubulin (microtubules). In addition, fusion, but not endocytosis-mediated
HIV-1 infectivity, was impaired when actin depolymerizing agents were added to target cells
before infection but not when added after infection. These results point to a previously unsus-
pected role for the host cell cytoskeleton in HIV-1 entry and suggest that components of the
cytoskeleton promote establishment of the reverse transcription complex in the host cell and
also the process of reverse transcription within this complex.
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fficient infection of a cell by the primate lentivirus
HIV-1 involves receptor engagement by the virus
and fusion between viral and host cell membranes (for a
review, see reference 1). After this initial interaction, a
poorly defined uncoating step leads to release of viral nu-
cleic acids from the capsid (gag CA)
 
1
 
 core. The uncoating
process ultimately results in the formation of a reverse tran-
scription complex that comprises the structural gag matrix
(MA) protein (2–7) and the enzymatic proteins, reverse
transcriptase and integrase (2, 3, 8), which are derived from
the virion and in which viral cDNA synthesis proceeds
(for a review, see reference 9). The structural gag MA pro-
tein is tightly associated with the reverse transcription
complex, and conditions that promote dissociation of inte-
grase do not affect association of gag MA (7). In addition,
gag MA within reverse transcription complexes is myris-
toylated (10), and this modification is important in pro-
moting membrane targeting of gag MA (within the con-
text of gag polyprotein) to the plasma membrane (11–13).
During virus entry, the membrane targeting property of
myristoylated gag MA is regulated by phosphorylation (6,
10, 14). Nonphosphorylated gag MA is predominantly lo-
calized to the cell membrane. Phosphorylated gag MA,
which is in viral reverse transcription complexes, is not
membrane-associated (10). This likely allows free translo-
cation of the reverse transcription complex from the point
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of virus entry to the host cell nucleus (6, 10, 14). Gag MA
has also been implicated in promoting the nuclear translo-
cation of viral reverse transcription complexes. Mutations
within a basic domain of gag MA that bears similarities to a
canonical nuclear localization signal (2, 3) influence nuclear
targeting of the reverse transcription complex in nondivid-
ing cells (2, 3, 5, 6, 15). However, mutations within the
basic domain are not sufficient to prevent the nuclear trans-
location step (16, 17), suggesting that additional virion pro-
teins promote translocation of the reverse transcription
complex to the nucleus. In support of this, several groups
have demonstrated that a virion-packaged accessory gene
product, Vpr, also associates with the viral reverse tran-
scription complex (5) and facilitates its nuclear translocation
(5, 18–22). A cooperative model of MA/Vpr nuclear im-
port has been suggested by the demonstration that gag MA
binds to karyopherin in a Vpr-dependent manner (23). In
addition, integrase has been shown to promote nuclear tar-
geting of the reverse transcription complex in a cooperative
manner with MA and Vpr proteins (18). While the actual
roles played by gag MA in virus entry are still being de-
fined, the protein represents a marker with which to moni-
tor the fate of the viral reverse transcription complex dur-
ing HIV-1 infection.
Several features of virus entry distinguish animal on-
coretroviruses from primate lentiviruses. The virion core of
oncoretroviruses and lentiviruses are comprised of gag CA
protein. Although the reverse transcription complexes of
oncoretroviruses such as murine leukemia virus (MLV)
contain gag CA (24), those of HIV-1 contain gag MA (2–4,
6, 7). The process that effects this rearrangement of virion
proteins during HIV-1 entry is not known. Similarly, there
is little information on how the process of reverse tran-
scription is initiated after formation of the reverse transcrip-
tion complex within the target cell. Reverse transcription
can be initiated within HIV-1 virions; however, the pro-
cess is very inefficient and results predominantly in syn-
thesis of early reverse transcripts (25–27). Although the
processes of HIV-1 reverse transcription and nuclear trans-
location proceed concurrently, reverse transcription in vivo
proceeds at 
 
z
 
1 nucleotide/s (28), whereas reverse tran-
scription complexes translocate to the host cell nucleus as
early as 1 h after infection (10, 29). Thus, after HIV-1 in-
fection it is likely that the majority of reverse transcription
complexes in the nucleus contain incomplete viral tran-
scripts that are still undergoing reverse transcription. After
MLV infection, where nuclear import is dependent on mi-
tosis, the majority of reverse transcription is completed be-
fore nuclear import (30–32).
To better understand early events in the life cycle of
HIV-1, we analyzed compartmentalization of viral reverse
transcription complexes in the host cell early after virus in-
fection. We demonstrate that viral reverse transcription
complexes rapidly associate with actin microfilaments of
the host cell cytoskeleton after infection. This association
was necessary for efficient entry of viral nucleic acids into
the target cell and for the efficient reverse transcription of
genomic viral RNA. These observations suggest a model in
which the cytoskeleton provides a cofactor or acts as a scaf-
fold for the appropriate localization and activation of the
viral reverse transcription complex and, ultimately, for effi-
cient infection of the cell by HIV-1.
 
Materials and Methods
 
Generation of Viral Stocks.
 
293T cells (33) were maintained in
DME supplemented with penicillin (100 U/ml), streptomycin
(100 
 
m
 
g/ml), and 10% fetal bovine serum (FBS). For generation
of viral stocks, 293T cells were transfected with HIV-1
 
LAI
 
 (34)
proviral DNA (25 
 
m
 
g) using a modified calcium phosphate/DNA
precipitation method (GIBCO BRL, Gaithersburg, MD) and in-
cubated at 37
 
8
 
C. Virions in culture supernatants were collected at
24 and 48 h after transfection and either used directly for infec-
tion or amplified in MT-4 T cells in RPMI 1640 supplemented
with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml strep-
tomycin, and 10% FBS. Pseudotype viruses were obtained after
cotransfection of 293T cells with a vesicular stomatitis virus
(VSV)-G envelope expression vector and an HIV-1
 
LAI
 
 clone con-
taining a 600-bp deletion in gp120 coding sequences as described
previously (35, 36). Calcium phosphate–transfected culture su-
pernatants were collected at 48 h after transfection. Virus particles
in culture supernatants were quantitated by measurement of re-
verse transcriptase activity. For preparation of 
 
32
 
P-gag MA–
labeled virions, productively infected CD4
 
1
 
 MT-4 cells were incu-
bated in the presence of 0.5 mCi ortho [
 
32
 
P]phosphate per ml in
phosphate-free medium containing 0.1% calf serum. After a 6-h
incubation, culture supernatants were cleared of cellular debris by
low-speed centrifugation (1,500 
 
g
 
, 10 min), and virions in clari-
fied supernatants were harvested after high-speed centrifugation
(10,000 
 
g
 
, 2 h).
 
Subcellular Fractionation.
 
Subcellular fractions of HIV-1–
infected MT-4 cells and HeLa-CD4-LTR/
 
b
 
-gal “Magi” cells
comprising cell membrane, cytosolic, cytoskeletal, and nuclear
extracts were prepared essentially as described elsewhere (20).
Cells were pelleted and washed in a hypotonic solution (10 mM
Hepes, pH 6.9, 10 mM KCl, 3 
 
m
 
l/ml aprotinin, 0.1 mM PMSF)
and incubated on ice in hypotonic solution for 15–20 min. Cells
were disrupted by dounce homogenization (20 strokes). Nuclei
were pelleted at 1,000 
 
g
 
 (3 min), supernatant was removed, and
nuclei were further purified by three successive washes (retained
as nuclear wash extract) in NTENT buffer (150 mM NaCl, 10
mM Tris-HCl, pH 7.2, 1 mM EDTA, 3 
 
m
 
l/ml aprotinin, 0.1
mM PMSF, 1% Triton X-100). Supernatant from pelleted nuclei
was further centrifuged at 14,000 
 
g
 
 for 30 min. The supernatant
(cytosolic fraction) was separated, and the pellet was further resus-
pended in NTENT and recentrifuged at 14,000 
 
g
 
 for 30 min.
The resulting pellet comprises the cytoskeletal fraction, while the
supernatant comprises the membrane fraction.
 
Western Blot Analysis.
 
Subcellular fractions from an equiva-
lent of 10
 
6
 
 cells were adjusted to 62.5 mM Tris-HCl, pH 6.8,
0.2% SDS, 5% 2-ME, 10% glycerol. Samples were denatured by
boiling and separated on 12% SDS-polyacrylamide gels. After
electrophoresis, proteins were transferred to nitrocellulose (Hy-
bond C Extra; Amersham Pharmacia Biotech, Inc., Piscataway,
NY), blocked in 5% milk, and incubated with the respective anti-
body. Bound antibodies were visualized with peroxidase anti-Ig
followed by enhanced chemiluminescence (ECL; Amersham
Pharmacia Biotech, Inc.). All Western blot images were within
the linear range of the ECL assay. Rhodamine-conjugated phal-
loidin and antibodies to tubulin, vimentin, actin, and myosin
were obtained from Sigma Chemical Co. (St. Louis, MO). For 
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those experiments comparing protein distribution between differ-
ent cellular compartments, cell lysate from an equivalent of 10
 
6
 
cells was resolved in each lane. This allowed for qualitative com-
parison of protein distribution between cellular compartments.
For those experiments comparing the effect of cytoskeletal inhib-
itors on protein distribution within the same cellular compart-
ment, the amount of total protein in each lane was adjusted to
equivalent levels and, as a consequence, more quantitative com-
parisons could be made.
 
Analysis of In Vivo Interaction between Cytoskeletal and Virion Pro-
teins.
 
MT-4 cells were harvested 1.5 h after infection. Lysates of
infected and uninfected cells were obtained by disruption of cells
in immunoprecipitation buffer (50 mM Hepes, pH 6.9, 10 mM
EDTA, 1% Triton X-100, 3 
 
m
 
l/ml aprotinin, 1 mM PMSF). The
extracts were centrifuged at 1,000 
 
g
 
 (3 min), and supernatants
were precleared with normal rabbit antiserum (6 h, 4
 
8
 
C). Pre-
cleared lysates were adjusted to 100, 300, and 800 mM NaCl. Vi-
ral proteins were immunoprecipitated with rabbit anti-CA and
anti-MA antibodies overnight at 4
 
8
 
C in the presence of protein A
and G. Bound immunoprecipitates were washed five times in im-
munoprecipitation buffer and resolved on 15% SDS-PAGE gels.
Proteins were transferred to Highbond C Extra (Amersham Phar-
macia Biotech, Inc.) and analyzed by Western blotting with anti-
bodies to tubulin, vimentin, actin, and myosin (Sigma Chemical
Co.). Bound antibodies were visualized with peroxidase anti-Ig,
followed by ECL (Amersham Pharmacia Biotech, Inc.).
 
Immunohistochemistry.
 
Cells were seeded onto 12-well plates
containing 0.13-mm-thick coverslips. Cells were grown for 24 h
at 37
 
8
 
C in DME containing 10% FBS, Hygromycin (100 
 
m
 
g/ml),
and G418 (200 
 
m
 
g/ml). For cytoskeletal staining, coverslips con-
taining adherent cells were removed and rinsed two to three
times with warm (37
 
8
 
C) PBS. Coverslips were placed in a petri
dish and permeabilized with a solution of 0.1% Triton X-100 in
PBS for 1 min, then washed twice with warm PBS. Cells were
then immediately placed in warm (37
 
8
 
C), freshly prepared form-
aldehyde-Triton solution (4% formaldehyde, 0.2% Triton X-100,
60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 3 mM MgCl
 
2
 
, pH
6.1) for 10 min. The coverslips were then rinsed two to three
times with room temperature PBS. To reduce nonspecific back-
ground staining, fixed cells were incubated with PBS containing
1% BSA for 15 min and washed twice with PBS before addition
of staining solutions. For staining of actin microfilaments, cells
were overlaid with 200 
 
m
 
l of a PBS/1% BSA solution containing
5 U/ml Texas Red phalloidin (Molecular Probes, Inc., Eugene,
OR). Cells were incubated at room temperature for 20–30 min
and then rinsed twice with PBS. For tubulin and vimentin visual-
ization, permeabilized cells were overlaid with PBS/1% BSA
containing tubulin (DM1A) and vimentin (V9) antibodies (Sigma
Chemical Co.) for 20 min. Cells were washed twice in PBS and
then incubated with FITC-conjugated donkey anti–mouse IgG
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Stained cells were mounted in Vectashield (Vector Laboratories,
Inc., Burlingame, CA) to minimize photo-bleaching. Images
were generated on a fluorescence microscope (Axioplan II; Carl
Zeiss, Jena, Germany) using the appropriate FITC and Texas Red
filter sets. Photographs were obtained with a Plan Apochromat
objective (63
 
3
 
 1.40) under oil immersion.
 
PCR Analysis of HIV-1 cDNA Synthesis.
 
Total cellular DNA
was isolated from acutely infected cells using an IsoQuick DNA
extraction protocol (Microprobe Corp., Bothell, WA). Minus-
strand HIV-1 strong-stop cDNA products were amplified using
LTR R (5
 
9
 
-g
 
635
 
 tgctagagattttccacactgac) and U5 (5
 
9
 
-g
 
496
 
 gctaac-
taggaacccactg) primers as described previously (37). Late reverse
transcription products were amplified by LTR R (5
 
9
 
-g
 
485
 
 ggagct-
ctctggctaact) and gag (5
 
9
 
-g
 
931
 
 gattaactgcgaatcgttc) primers. Viral
cDNA was amplified in 10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl
 
2
 
, and 0.001% (wt/vol) gelatin. After the initial de-
naturation (95
 
8
 
C, 2 min), amplification proceeded for 25 or 35
cycles of PCR (95
 
8
 
C, 30 s; 58
 
8
 
C, 30 s; 72
 
8
 
C, 1 min) followed by
a final 5-min extension at 72
 
8
 
C. HIV-1 copy number standards
were generated by PCR on serial twofold dilutions of 8E5 cells
(each cell containing a defective provirus [38]). PCR products
were Southern blotted onto nylon membranes and hybridized
with a mixture of two 
 
32
 
P-labeled oligonucleotide probes (5
 
9
 
-g
 
566
 
tctgttgtgactctggt, 5
 
9
 
-g
 
584
 
 taactagagatccctcagac) for detection of
both early and late products of reverse transcription. Primers
are numbered according to the HIV-1
 
HXB2
 
 sequence (39). Hy-
bridized PCR products were visualized on a PhosphorImager
(Molecular Dynamics, Sunnyvale, CA). Hybridized products
were quantitated by volume integration (local mean background
subtraction was applied) using ImageQuant software (Molecular
Dynamics).
 
Single-cycle Infectivity Assays.
 
HeLa-CD4-LTR/
 
b
 
-gal Magi in-
dicator cells (35) were plated in 96-well microtiter plates (2 
 
3 
 
10
 
4
 
cells/well). HIV-1 virions (normalized to reverse transcription ac-
tivity) were added in doubling dilutions to triplicate wells. At 48 h
after infection, cells were harvested for quantitation of 
 
b
 
-galac-
tosidase production after hydrolysis of X-gal in vitro (Promega
Corp., Madison, WI).
 
Results
 
Viral Reverse Transcription Complexes Rapidly Associate with
the Host Cell Cytoskeleton.
 
Gag MA is tightly associated
with the viral transcription complex (2, 3, 7) likely through
a high-affinity interaction with genomic viral RNA (40;
our unpublished results), and thus represents a marker with
which to follow the distribution of the reverse transcription
complex in the infected cell. At 1 h after infection, MT-4
cells were fractionated into cytoplasmic, nuclear, cytoskele-
tal, and membrane fractions. The purity of the fractions
was assessed by Western blotting with antibodies to cyto-
skeletal proteins (actin, tubulin), nuclear proteins (histone
H1), and membrane proteins (CD4). Cytoskeletal proteins
were detected primarily in cytosolic and cytoskeletal frac-
tions and were absent from the nucleus (Fig. 1 
 
A
 
). Actin is
present in the cell in two forms, as polymerized filaments
and as unpolymerized monomers. Polymerized actin is
enriched in cytoskeletal fractions, whereas much of the
actin that is recovered from cytosolic extracts is in the
unpolymerized form. The degree of actin polymerization
varies between experiments and, as a consequence, the
amount of actin recovered in cytosolic fractions varies
between experiments. Histone H1 was present in nuclear
fractions but not cytosolic or cytoskeletal fractions. CD4,
the principal receptor for HIV-1, was restricted to mem-
brane and cytoskeletal fractions, in agreement with pre-
vious reports (41, 42). Gag MA was found in all fractions
with the exception of the cytoplasm (Fig. 1 
 
B
 
). We and
others have previously demonstrated that gag MA that is
associated with reverse transcription complexes is phospho-
rylated whereas that associated with membranes is not (6, 
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10, 14). Upon infection of cells with HIV-1 virions con-
taining 
 
32
 
P-gag MA, phosphorylated gag MA protein was
localized exclusively to the nucleus and to the cytoskeleton
(Fig. 1 
 
C
 
). In agreement with our previously published re-
sults (10), phosphorylated gag MA was excluded from the
membrane despite the fact that the majority of gag MA in
the acutely infected cell remains membrane associated (Fig.
1, 
 
B
 
 and 
 
C
 
). Thus, gag MA in the cytoskeletal fraction was
associated with viral reverse transcription complexes and
did not represent contamination of that fraction with
membrane-associated virion proteins. To examine the ki-
netics with which viral reverse transcription complexes as-
sociated with the cytoskeleton and the nucleus, cells were
infected and subcellular fractions were prepared at early in-
tervals after infection. Gag MA appeared in the cytoskele-
ton within 20 min of infection (Fig. 1 
 
D
 
), whereas its ap-
pearance in the nucleus was not evident until 60 min after
infection (Fig. 1 
 
D
 
).
We next determined whether the association of the re-
verse transcription complex with the cytoskeleton was sen-
sitive to cytoskeleton-disrupting agents. MT-4 cells were
treated for 2 h with cytochalasin D (CCD, 5 
 
m
 
M), a spe-
cific inhibitor of actin polymerization (43, 44). Cells were
then infected with HIV-1 and infection was allowed to
proceed in the absence of CCD. At 1 h after infection,
there was a reduction in the amount of gag MA present in
the cytoskeletal and nuclear fractions, whereas there was a
slight increase in the amount of gag MA associated with the
membrane (Fig. 2 
 
A
 
). Since infection proceeded in the ab-
sence of CCD and the effects of CCD are reversible, there
was a slight restoration of gag MA association with the cy-
toskeleton and nucleus when the distribution was exam-
ined at 5 h after infection (Fig. 2 
 
A
 
). In comparison, treat-
ment of cells with demecolcine, which causes perinuclear
aggregation of intermediate filaments (45), or with nocoda-
zole, a specific inhibitor of tubulin polymerization into mi-
crotubules (46), did not significantly affect the association
of gag MA with the cytoskeleton (Fig. 2 
 
B
 
). The inhibitory
effects of CCD were dependent on the time of drug addi-
tion. When cells were treated with CCD for either 1 or 2 h
before virus infection, the amount of gag MA in the cy-
toskeleton and in the nucleus was markedly reduced (Fig. 2
 
C
 
). The presence of gag MA in the cytoskeleton or nucleus
was not significantly affected if CCD was added as early as
1 h after infection (Fig. 2 
 
C
 
). Treatment of cells with CCD
inhibits actin polymerization; however, monomeric actin
could still be recovered from the cytoskeletal fraction of
CCD-treated cells (Fig. 2 
 
D
 
). In addition, inhibition of ac-
tin polymerization resulted in an increase in the amount of
actin recovered from the cytosolic fraction, likely as a con-
sequence of increased levels of monomeric actin. The pres-
ence of gag MA in the cytoskeletal and nuclear fractions of
cells treated with CCD after virus infection suggests that
the interaction between the reverse transcription complex
and the cytoskeleton is retained whether actin is mono-
meric or polymerized. Since gag MA rapidly associates
with the cytoskeleton, and CCD did not affect this associa-
tion when added 1 h after infection, the results suggest that,
once established, the interaction between the reverse tran-
scription complex and the cytoskeleton is not reversed
upon actin depolymerization.
 
Interaction between Gag MA and Actin In Vivo.
 
We next
investigated the mechanism by which viral reverse tran-
scription complexes associated with the cytoskeleton. Re-
cent studies have suggested an interaction between HIV-1
gag polyprotein and F-actin present in microfilaments (47).
Therefore, we determined whether the two major pro-
cessed products of gag polyprotein in the virion, namely
gag MA and gag CA, associated with actin in vivo. Cell ex-
tracts were prepared from uninfected MT-4 cells and from
MT-4 cells 1 h after HIV-1 infection. Lysates of infected
and uninfected cells were adjusted to 100, 300, and 800
mM NaCl and immunoprecipitated with antibodies to gag
MA or gag CA (Fig. 3 
 
A
 
). The presence of cytoskeletal
proteins in these immunoprecipitates was then determined
by Western blotting with antibodies to cytoskeletal pro-
teins including actin (microfilaments), vimentin (interme-
diate filaments), or tubulin (microtubules) and to gag MA
and gag CA as outlined in Fig. 3 
 
A
 
. Antibodies to actin re-
acted with gag MA immunoprecipitates from HIV-1–
infected cells at 100, 300, and 800 mM NaCl, suggesting a
tight interaction between actin and gag MA (Fig. 3 
 
B
 
). Gag
MA immunoprecipitates from uninfected cells also reacted
with actin antibody but only at 100 mM NaCl, likely a re-
sult of a nonspecific interaction between actin and a cellular
protein within gag MA immunoprecipitates (Fig. 3 
 
B
 
). In
comparison, antibodies to actin bound to gag CA immuno-
Figure 1. Association of viral
reverse transcription complexes
with the cytoskeleton. MT-4
cells were infected with HIV-1,
and at 1 h after infection, cells
were fractionated as detailed in
Materials and Methods (sizes to
the right in kD). Subcellular
fractions were examined for the
presence of cellular proteins (A)
and virion-derived gag MA pro-
tein (B). The distribution of
phosphorylated (Phospho.) gag
MA, which specifically associ-
ates with the reverse transcription complex, is shown in C. MT-4 cells
were fractionated at various intervals after HIV-1 infection, and the distri-
bution of gag MA in various cellular compartments was determined by
Western blotting (D). All Western blot images are within the linear range
of the ECL assay. For A, B, and C, cell lysate from a total of 106 cells was
loaded in each lane. 
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precipitates prepared in 100 mM NaCl but not in 300 or
800 mM NaCl. This weak interaction was again nonspe-
cific since it was evident in both infected and uninfected
cells (Fig. 3 
 
B
 
). No reactivity of gag MA or gag CA immu-
noprecipitates was noted with antibodies to vimentin or to
tubulin (Fig. 3 
 
B), suggesting that there was no association
between these proteins in acutely infected cells. Each anti-
body recognized its cognate protein at all NaCl concentra-
tions, indicating that the high salt immunoprecipitation
conditions did not compromise antibody reactivity (Fig. 3
C). Collectively, these results suggest that gag MA associ-
ates with actin during early stages of HIV-1 infection.
Efficient Reverse Transcription of HIV-1 Nucleic Acids In-
volves the Cytoskeleton. To determine whether the cyto-
skeletal association of viral reverse transcription complexes
influenced the function of this complex, we initially deter-
mined whether cytoskeletal depolymerizing agents influ-
enced cDNA synthesis within the complex. According to
current models of reverse transcription (48), the earliest vi-
ral cDNA detectable in the cell after fusion and uncoating
is minus-strand strong-stop cDNA which spans the R-U5
region of the viral LTR (Fig. 4 A), whereas a late step in
reverse transcription involves synthesis of plus-strand DNA
spanning the LTR U5/gag boundary (Fig. 4 A). Thus,
LTR R-U5 products represent a marker with which to
gauge the extent of virus entry and early reverse transcrip-
tion, whereas LTR U5-gag products provide an indicator
of the extent of late reverse transcription in the infected cell
(37). CCD (5 mM) was added to cells 1 h before or 2 h af-
ter virus infection. Cells were harvested 4 h after virus in-
fection for isolation of viral nucleic acids from membrane/
cytosol, cytoskeletal, and nuclear extracts. Early (LTR R-U5)
Figure 2. Inhibitors of actin polymerization reduce cy-
toskeletal association of viral reverse transcription com-
plexes. (A) MT-4 cells were treated for 2 h with CCD (5
mM), which prevents actin polymerization. Cells were
then infected with HIV-1 and fractionated at 1 and 5 h af-
ter infection (P.I.) for analysis of gag MA distribution. (B)
MT-4 cells were treated with nocodazole (10 mM), an in-
hibitor of tubulin polymerization into microtubules, or de-
mecolcine (10 mM), which causes disaggregation of inter-
mediate filaments. Gag MA in the cytoskeleton was
examined by Western blotting 1 h after infection. (C)
MT-4 cells were incubated with CCD for 1 and 2 h before
infection or 1 and 2 h after infection. At 3 h after infection,
cytoskeletal and nuclear extracts were prepared and exam-
ined for the presence of gag MA by Western blotting. (D)
The subcellular distribution of actin was examined by
Western blotting in MT-4 cells (Control) and in MT-4 cells
after a 2-h incubation with CCD. For A, B, and C, equal
amounts of cellular protein were loaded in each lane. In D,
each lane contains lysate from 106 cells.
Figure 3. Interaction between cytoskele-
tal proteins and HIV-1 gag MA in vivo. (A)
Cell lysates of HIV-1–infected and unin-
fected MT-4 cells were immunoprecipitated
with antibodies to gag MA and gag CA in
100, 300, and 800 mM NaCl. The presence
of viral and cytoskeletal proteins in gag MA
and gag CA immune complexes was exam-
ined by Western blotting (B) with antibod-
ies to viral (gag MA, gag CA) and cytoskel-
etal (actin, tubulin, vimentin) proteins. (C)
Western blot analysis of cytoskeletal pro-
teins in cell lysates at different NaCl con-
centrations.2118 Cytoskeletal Dependence of HIV-1 Reverse Transcription
and late (LTR U5-gag) cDNA products of reverse tran-
scription in these extracts were analyzed by PCR under
limiting dilution conditions. In untreated (control) cells,
early reverse transcripts were detectable in all subcellular
fractions (Fig. 4 B). Surprisingly, late products of reverse
transcription were found only in cytoskeletal and nuclear
fractions but were absent from membrane/cytosol extracts
(Fig. 4 B). When added 1 h before infection, CCD re-
duced the amount of early reverse transcripts in all fractions
by approximately four- to fivefold (Fig. 4 B). Late products
were not detectable in the cytoskeleton of CCD-treated
cultures, whereas in the nucleus their abundance was re-
duced by z25-fold (Fig. 4 B). In contrast, addition of
CCD to cells 2 h after virus infection had no effect on
abundance of either early or late products of reverse tran-
scription in any cell fraction (Fig. 4 B). Both early and late
cDNA products were the result of de novo reverse tran-
scription rather than virion-associated cDNA products,
since the amount of PCR products was markedly reduced
in cultures that had been pretreated with the reverse tran-
scriptase inhibitor, AZT (Fig. 4 B). The results suggest that
steps in virus entry leading up to initiation of reverse tran-
scription (fusion/uncoating, activation of the reverse tran-
scription complex) involve the cytoskeleton. The results
further indicate that the reverse transcription process is lo-
calized primarily on the cytoskeleton and that efficient syn-
thesis of late cDNA transcripts requires the presence of actin
microfilaments. This interaction with the cytoskeleton ap-
pears to be initiated early upon infection and is also irrevers-
ible, since addition of CCD to cells after virus infection did
not compromise the reverse transcription process (Fig. 4 B).
Efficient HIV-1 Infection Requires an Intact Cytoskeleton.
A confounding factor in experiments that examine early
events in the virus life cycle is that much of the viral mate-
rial present in the inoculum is noninfectious. Thus, it is
possible that the viral nucleic acids and proteins found in
association with the cytoskeleton may not be the compo-
nent of the inoculum that was actually mediating bona fide
virus infection. To address this issue, we examined the ef-
fects of cytoskeletal inhibitors on HIV-1 infection. After
completion of reverse transcription, viral nucleic acids inte-
grate into host cell DNA, leading to the formation of a
“provirus” from which genomic and subgenomic viral
transcripts are derived. Therefore, we examined the effects
of cytoskeletal inhibitors on provirus establishment in a sin-
gle-cycle Magi infectivity assay (35). We initially deter-
mined drug concentrations required to impair organization
of their cognate cytoskeletal targets in Magi cells (Fig. 5 A).
In adherent cells, actin is organized in “stress fibers” of po-
lymerized actin microfilaments (Fig. 5 A). Treatment of
cells with cytochalasins A, D, and E (5 mM) led to a col-
lapse of actin microfilaments into condensed bundles of
monomeric actin that was randomly distributed through
the cell cytoplasm (Fig. 5 A). This concentration of cyto-
chalasin did not compromise cell viability during the course
of the experiment (not shown). Complete disruption of ac-
tin microfilaments typically occurred within 1 h of drug
addition. All three cytochalasins (CCA, CCD, and CCE)
markedly impaired viral infectivity when added 2 h before
(2h pre) virus infection (Fig. 5 B). In contrast, the drugs did
not significantly affect HIV-1 infectivity when added 2 h
after (2h post) virus infection, and in some cases enhanced
Figure 4. Efficient HIV-1 reverse transcription requires actin microfilaments. (A) Schematic of the major steps involved in synthesis of HIV-1 cDNA.
Broken lines, genomic RNA; solid lines, cDNA; short arrows, regions of the viral genome to which PCR primers are directed; asterisk, the primer binding
site. R-U5 and U5-gag primers amplify predominantly early and late products of reverse transcription, respectively. (B) HIV-1–infected MT-4 cells were
incubated in the presence or absence of CCD (5 mM, added 1 h before or 2 h after HIV-1 infection), and subcellular fractions were prepared at 3 h after
infection. Lysates were treated with DNAse to remove carryover DNA in the inoculum (reference 37). Early (LTR R-U5) and late (LTR U5-gag) prod-
ucts of reverse transcription in cell fractions were quantitated by PCR in serial fivefold dilutions of the cellular lysate. Infections carried out in the pres-
ence of AZT (5 mM) were used to verify de novo synthesis of viral cDNA. PCR products were visualized by Southern blot hybridization to HIV-1–spe-
cific oligonucleotide probes as outlined in Materials and Methods.2119 Bukrinskaya et al.
infection (Fig. 5 B). Thus, the inhibitory effects of the cy-
tochalasins on HIV-1 infectivity were not due, for exam-
ple, to indirect effects of the drugs on host cell viability.
This pattern of inhibition is in strong agreement with the
effect of these inhibitors on the association of gag MA with
the cytoskeleton (Figs. 2 and 3) and on reverse transcrip-
tion (Fig. 4) in MT-4 cells, in that CCD was inhibitory
when added at least 1 h before but not after virus infection.
We next determined whether there was a concomitant ef-
fect on the reverse transcription process in Magi cells. Early
(LTR R-U5) and late (LTR U5-gag) products of reverse
transcription were quantitated at different intervals after in-
fection (Fig. 6). Treatment of CCD only slightly impaired
the levels of minus-strand strong-stop cDNA in all fractions
(Fig. 6). In agreement with the pattern observed in MT-4
cells, late products of reverse transcription were evident
only in the cytoskeleton and the nucleus. However, pre-
treatment of the cells with CCD delayed the appearance of
late products of reverse transcription (Fig. 6). In untreated
cells, late products of reverse transcription were detectable
in the cytoskeleton and the nucleus at 1 and 3 h after infec-
tion, respectively. After CCD treatment, late reverse tran-
scription products could not be detected until 5 h after in-
fection (Fig. 6). In contrast to the inhibitory effects of
cytochalasins on HIV-1 entry, the microtubule disrupting
agent, nocodazole, had a very modest inhibitory effect on
HIV-1 infectivity in several independent experiments (Fig.
7). Although a slight inhibitory effect on HIV-1 infectivity
was observed at lower levels of virus inoculum, these ef-
fects were equally apparent whether nocodazole was added
before or after HIV-1 infection. Since nocodazole had no
effect on the interaction between gag MA and the cyto-
skeleton or on the abundance of gag MA in the acutely in-
fected cell (Fig. 2 B), it is unlikely that nocodazole is di-
rectly influencing establishment of the reverse transcription
complex. Since the slight inhibitory effect was evident
when the inhibitor was added before and after virus infec-
tion, we cannot exclude the possibility that nocodazole in-
fluenced the infectivity assay indirectly through its effect on
host cell function. Collectively, these results indicate that
the reverse transcription process in a newly infected cell is
localized to the host cell cytoskeleton and that intact actin
microfilaments are necessary for efficient reverse transcrip-
tion.
Actin–Myosin Interaction Influences HIV-1 Infection. Trans-
lational movement along actin microfilaments is mediated
by myosins (for a review, see reference 49). Myosin func-
tion is regulated by phosphorylation of the regulatory light
Figure 5. Actin microfilaments are required for efficient HIV-1 infection. (A) Immunohistochemical analysis of HeLa-CD4-LTR/b-gal indicator cells
with rhodamine-phalloidin after a 1-h incubation with the actin depolymerizing agents CCA, CCD, and CCE (5 mM). In untreated (Control) cells, actin
filaments are organized in linear array stress fibers of polymerized actin. Cytochalasin (5 mM) was sufficient to almost completely prevent actin polymer-
ization in these cells. (B) Magi cells were incubated with the indicated cytochalasins for 2 h before (2h pre) and 2 h after (2h post) virus infection. Infected
cells were harvested 48 h later for quantitation of b-galactosidase production. Cell infection was evaluated at five different levels of input virus in triplicate
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chains by myosin light-chain kinase (50), which promotes
myosin ATPase activity and polymerization of actin cables
(51, 52). ML7 (53) and KT5926 (54; both obtained from
Calbiochem Corp., La Jolla, CA) are well-described inhib-
itors of myosin light-chain kinase (Ki; 21 mM and 18 nM,
respectively). Inhibition of myosin light-chain phosphory-
lation inhibits myosin-mediated translational movement.
Thus, we examined whether HIV-1 infectivity was sensi-
tive to agents that affect myosin-mediated translational
movement along actin microfilaments. The myosin light-
chain kinase inhibitors ML7 (Fig. 8 A) and KT5926 (Fig. 8
B) both impaired viral infectivity. This inhibition was simi-
lar to that observed with cytochalasins, in that ML7 inhib-
ited HIV-1 infection when added 2 h before virus infec-
tion, but not 2 h after infection. Subcellular distribution of
viral reverse transcription complexes in cells treated with
KT5926 was determined in order to identify at which
point the inhibition of infectivity was manifest. Pretreat-
ment of cells with increasing concentrations of KT5926
between 100 and 500 nM resulted in a gradual decrease in
the amount of gag MA that localized to the host cell nu-
cleus, while there was a corresponding increase in the level
of gag MA in the cytoskeletal fraction (Fig. 8 C). One ex-
planation for this result is that inhibition of myosin phos-
phorylation delays the transit of viral reverse transcription
complexes from the cytoskeleton to the nucleus. KT5926
also reduced the amount of gag MA that was present in the
cytosol and membrane fractions by z30%, indicating that
viral uptake was also being influenced (Fig. 8 C). However,
this modest effect on gag MA uptake was not dose depen-
dent and was unlikely to account for the rather dramatic ef-
fect of this inhibitor on virus infection. Thus, although ad-
ditional effects of the inhibitor on virus uptake cannot be
excluded, the inhibitory profiles are more consistent with
the hypothesis that the effects of the inhibitor on gag MA
redistribution between cytoskeletal and nuclear fractions
account for the majority of the inhibitory effects on virus
infection.
The Host Cell Cytoskeleton Is Important for HIV-1 Entry by
Fusion but not by Endocytosis. HIV-1 entry is mediated by
pH-independent fusion between viral and host cell mem-
branes (55). When HIV-1 virion cores are pseudotyped
with envelope proteins of VSV, infection is mediated by
endocytosis (35, 56). Thus, we compared the relative cy-
toskeletal requirements for virus entry via the fusion and
endocytosis routes. In contrast to the marked effects of
CCD on wild-type HIV-1 infection (Fig. 5 B), CCD had
no significant effect on entry of VSV-pseudotyped HIV-1
when added before virus inoculation (Fig. 9 A). Similarly,
CCD had no effect on the association of gag MA with the
cytoskeleton (Fig. 9 B). Although a slight inhibitory effect
on virus infection was evident in cultures in which the in-
hibitor was added 2 h after virus inoculation (Fig. 9 A), this
very slight effect was not consistent over several indepen-
dent infectivity experiments and likely fell within the vari-
ability of the single-cycle infectivity assay. These results
suggest that cytoskeletal association can be uncoupled from
infectivity when HIV-1 entry is mediated by endocytosis.
It is possible that engagement of the cytoskeleton is cou-
pled to fusion, which places the reverse transcription com-
Figure 6. Efficient synthesis of late reverse transcription products re-
quires actin microfilaments. Untreated (Control) and CCD-treated Magi
cells (5 mM CCD added 2 h before virus infection) were harvested at dif-
ferent intervals after infection, and early and late products of reverse tran-
scription in different subcellular compartments were examined by PCR
using LTR R-U5 and LTR U5-gag primers, respectively.
Figure 7. HIV-1 infection does not require microtubules. (A) Organi-
zation of microtubules in Magi cells after incubation (2 h) with nocoda-
zole, a microtubule depolymerizing drug that fixes monomers of tubulin.
(B) Single-cycle HIV-1 infectivity characteristics in untreated and no-
codazole-treated Magi cells. Infectivity was analyzed in triplicate at six
different levels of input virus. Effects of nocodazole on single-cycle HIV-1
infection of Magi cells are as outlined in the legend to Fig. 5.2121 Bukrinskaya et al.
plex in an appropriate context within the acutely infected
cell (i.e., in association with the cytoskeleton). The experi-
ments also indicate that, upon establishment of a functional
reverse transcription complex within the cell (whether after
fusion or endocytosis), events in the viral life cycle leading
up to de novo gene expression from the integrated provirus
do not require actin microfilaments.
Discussion
The results outlined in this study suggest that an essential
early event in the virus life cycle, namely establishment of
the viral reverse transcription complex, is promoted by ac-
tin microfilaments of the host cell cytoskeleton. During
preparation of this manuscript, Iyengar et al. (57) demon-
strated that HIV-1 infection of primary T cells could be
completely inhibited by treatment of cells with CCD. The
investigators went on to demonstrate that colocalization of
the HIV-1 receptors, CD4 and CXCR4, on primary T
cells required actin, and suggested that actin is necessary for
a step leading up to fusion between viral and host cell
membranes. However, the results presented here clearly in-
dicate that the inhibitory effects of the cytochalasins in T
cells and Magi cells can only be partly accounted for by
inhibition of a step leading up to entry of the reverse tran-
scription complex. In the experiments presented here,
minus-strand strong-stop cDNA was detected in CCD-
treated T cells and Magi cells which completely lack actin
microfilaments. Our results indicate that the reverse tran-
scription complex rapidly associates with actin microfila-
ments and that efficient reverse transcription is dependent
on the presence of actin microfilaments. Our results also
suggest that actin microfilaments of the host cell cytoskele-
ton are a major site for reverse transcription in the infected
cell. Although actin depolymerization did not significantly
affect the presence of early reverse transcription products in
the cytoskeleton and in the nucleus, these early reverse
Figure 8. Inhibitors of myosin light-chain kinase impair HIV-1 infec-
tivity. Single-cycle infectivity analysis of HIV-1 was examined in Magi
cells treated with myosin light-chain kinase inhibitors ML-7 (20 mM) and
KT5926 (A and B, respectively). (C) Gag MA distribution in cytosol/
membrane, cytoskeletal, and nuclear extracts of Magi cells after treatment
with the indicated concentrations of KT5926 was examined by Western
blotting. Relative amounts of gag MA in each sample were determined
by volume integration (ImageQuant software; Molecular Dynamics).
Figure 9. Actin microfilaments are not required for HIV-1 infection
via endocytosis. (A) Effect of CCD on single-cycle infectivity of VSV-G–
pseudotyped HIV-1. Virions containing VSV envelope proteins were ob-
tained after cotransfection of an HIV-1 envelope minus mutant with
VSV-G expression vector. Pseudotyped virions were obtained from trans-
fected cell supernatants, and infectivities were determined in CCD-treated
and untreated Magi cells. (B) Untreated (Control) and CCD-treated (10 mM
CCD added 2 h before infection) Magi cells were infected with VSV-G–
pseudotyped HIV-1 virions. Cytoskeletal and nuclear extracts were pre-
pared 4 h after infection for analysis of gag MA distribution by Western
blotting.2122 Cytoskeletal Dependence of HIV-1 Reverse Transcription
transcription products did not go on to complete reverse
transcription if actin polymerization was inhibited before
virus infection. This suggests that interaction with actin mi-
crofilaments is an essential intermediate step that is required
for efficient reverse transcription, and early reverse tran-
scripts that bypass this intermediate step still translocate to
the nucleus but are incapable of undergoing complete re-
verse transcription. The basis for the dependence of an in-
tact cytoskeleton for efficient reverse transcription is un-
clear at present, and we know of no precedent in the
animal oncoretrovirus or primate lentivirus systems to ex-
plain this dependence. Cytoskeletal proteins have also been
implicated in the activation of transcription of paramyxovi-
ruses (measles virus, Sendai virus, respiratory syncytial vi-
rus) and rhabdoviruses (VSV) (58–60). For example, in
paramyxoviruses such as human parainfluenza virus type 3,
polymerized actin has been shown to be necessary for the
activation of transcription from the ribonucleoprotein com-
plex in vitro and in vivo (61–63). It has been suggested that
upon interaction with actin, the paramyxovirus ribonucle-
oprotein complex undergoes a conformational alteration
from a loosely coiled to a moderately condensed form,
which facilitates transcription (62). It is possible that activa-
tion of HIV-1 reverse transcription also requires a confor-
mational change in the reverse transcription complex, and
that this is mediated through interaction with the actin mi-
crofilaments. Although there is no direct evidence to sug-
gest that activation of the reverse transcription complex re-
quires interaction with the cytoskeleton, such a model is
suggested by the demonstration that the large subunit of
HIV-1 reverse transcriptase interacts with b-actin (64). Al-
though this interaction has been implicated in promoting
the release of virus particles from the infected cell, in light
of our current findings it is tempting to speculate that such
an interaction may provide the basis by which association
with actin microfilaments was required for efficient reverse
transcription. Alternatively, the uncoating process itself
may be facilitated by association of the incoming capsid
core with the cytoskeleton, due to the interaction between
capsid protein and actin. However, the results presented
here would favor the former hypothesis in that gag MA
within the reverse transcription complex associated with
actin, whereas capsid, the major component of the viral
core, did not exhibit any significant binding. The infectious
virus particle does not contain all the components necessary
for efficient completion of cDNA synthesis, since only
early reverse transcription products are reconstituted in in
vitro reverse transcription reactions using extracts from dis-
rupted virions (for a review, see reference 65). Thus, it is
also possible that the cytoskeleton is a favored site for re-
verse transcription because cellular factors important in the
reverse transcription process may also localize to the cy-
toskeleton.
VSV-G envelope–pseudotyped HIV-1 entry was inde-
pendent of actin microfilaments, suggesting that virus entry
by endocytosis circumvents the aspect of the virus life cycle
that requires cytoskeletal interaction. Entry of pseudotyped
HIV-1 by endocytosis requires an acidification step which
promotes fusion between the viral membrane and the
membrane of the endocytic vesicle (56). It is possible that
the low pH environment of the endosome may also alter
conformation of the viral reverse transcription complex in a
way that obviates the requirement for actin in this process.
By analogy, the requirement for actin microfilaments in the
entry of MLV also depends on the route of virus entry.
MLV infection of NIH 3T3 cells occurs by endocytosis,
whereas that of XC Sarcoma cells proceeds by surface fu-
sion. Both entry mechanisms are dependent on polymer-
ized actin, implicating a critical role for this network in an
early step common to both entry pathways, perhaps at the
level of receptor clustering (66, 67). However, events in
the entry process subsequent to virus uptake via endocyto-
sis, but not by fusion, were dependent on intact microtu-
bules, implicating the microtubule component of the cy-
toskeleton in a postpenetration step (67).
Previous studies have implicated the host cell cytoskele-
ton in late events in the virus life cycle. The release of
HIV-1 from polarized cells was shown to be dependent on
an intact cytoskeleton (68), whereas inhibitors of myosin
light-chain kinase and actin polymerization inhibited the
release of HIV-1 from the infected cells (69). Polymerized
actin has been implicated in directional budding of HIV-1
from infected monocytes as evidenced by colocalization of
actin and gag CA protein at the sites of virus release (23). A
role for the cytoskeleton in virus release was also suggested
by the observation that HIV-1 gag polyprotein associated
with polymerized actin (47) and that HIV-1 virions contain
actin in a 10% molar ratio relative to gag polyproteins (70).
The accessory gene product, Vif, which has an important
role in the regulation of virus infectivity, has been proposed
to regulate virus maturation by mediating interaction with
the cellular cytoskeleton (71). The role of gag–cytoskeleton
interaction in virus maturation may be paradoxical with the
potential role of gag MA–cytoskeletal interaction during vi-
rus entry. Presumably, the interaction between gag precursor
proteins and the cytoskeleton at late stages in the virus life
cycle would favor accumulation of virion precursor proteins
at the cell surface, which is necessary for efficient budding
from the infected cell. However, as shown in this study, at
early stages in the virus life cycle this interaction appears to
be promoting the establishment of infection after virus
uptake. Our data suggest that phosphorylated gag MA pro-
teins of the virion associate with the cytoskeleton. This dif-
ferential phosphorylation likely dictates the fate of the rep-
lication intermediates that have associated with the
cytoskeleton. We have previously suggested a model in
which gag MA phosphorylation regulates the opposing tar-
geting properties of this protein during virus assembly and
during virus entry (10, 14).
Recent studies have suggested that nuclear targeting of
incoming human foamy virus proteins was dependent on
the presence of intact microtubules (72). Similar to the lo-
calization of viral reverse transcription complexes to actin
microfilaments outlined here, the study of Saib et al. (72)
demonstrated aggregation of viral reverse transcription com-
plexes on microtubules. That study also suggested that virus2123 Bukrinskaya et al.
entry was not dependent on microtubules but that a subse-
quent step, either at the level of reverse transcription or
nuclear import, was microtubule dependent and highly
sensitive to colchicine, a microtubule-disrupting agent.
These results are reminiscent of observations in other viral
systems such as herpes simplex, where transport of incom-
ing viral capsids to the nucleus is mediated by microtubules
(73). Intriguingly, recent studies in our laboratory (our un-
published results) suggest that intermediate filaments, an-
other component of the cytoskeleton, do not appear to be
involved in events leading up to completion of viral cDNA
synthesis on the cytoskeleton but may be important for
subsequent translocation of nascent viral reverse transcrip-
tion complexes to the host cell nucleus.
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